Tenaya Therapeutics Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Tenaya Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.55 $ to 2.10 $ · Last price: 0.6096 $ (As of: September 25, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/25/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Tenaya Therapeutics Inc TNYA | 0.1 | – | -0.7 | 100.0 | -1,882.8 | – | -60.3 |
| Vertex Pharmaceuticals Inc VRTX | 133.1 | 31.9 | 24.4 | 55.0 | 38.1 | 9.6 | 37.8 |
| Regeneron Pharmaceuticals Inc REGN | 81.9 | 19.8 | 13.5 | 44.5 | 20.7 | 1.0 | 38.7 |
| Moderna Inc MRNA | 78.9 | – | 4.6 | -66.0 | -131.1 | -39.2 | 708.1 |
| argenx NV ARGX | 59.7 | 36.7 | 31.5 | 59.1 | 32.0 | 89.6 | 31.9 |
| Revolution Medicines Inc RVMD | 42.6 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 359.0 |
| BeiGene, Ltd. ONC | 40.8 | 64.4 | 32.4 | 88.9 | 19.1 | 40.2 | 9.1 |
| Alnylam Pharmaceuticals Inc ALNY | 34.0 | 64.4 | 28.6 | 79.7 | 23.0 | 65.2 | -45.6 |
| Royalty Pharma Plc RPRX | 32.1 | 31.4 | 19.2 | 95.8 | 100.3 | 5.1 | 70.0 |
| Median of companies shown | 42.6 | 34.3 | 19.2 | 59.1 | 20.7 | 7.3 | 37.8 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 0 | -28 | -26 | -0.95 | -24 | -44 | 38 |
| 2020 | 0 | -39 | -38 | -0.93 | -35 | 139 | 148 |
| 2021 | 0 | -73 | -70 | -1.69 | -61 | 279 | 317 |
| 2022 | 0 | -126 | -124 | -2.76 | -104 | 243 | 279 |
| 2023 | 0 | -131 | -124 | -1.68 | -102 | 139 | 171 |
| 2024 | 0 | -116 | -111 | -1.31 | -91 | 93 | 120 |
| 2025 | 0 | -93 | -91 | -0.59 | -68 | 123 | 147 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q3 | -0.30 | 23.10 | 0 | – | – | -20 | -20 |
| 2024: Q4 | -0.28 | 30.00 | 0 | -100.00 | – | -18 | -19 |
| 2025: Q1 | -0.24 | 40.00 | 0 | – | – | -23 | -24 |
| 2025: Q2 | -0.14 | 58.80 | 0 | – | – | -16 | -16 |
| 2025: Q3 | -0.12 | 60.00 | 0 | – | – | -16 | -16 |
| 2025: Q4 | -0.12 | 57.10 | 0 | – | – | -14 | -14 |
| 2026: Q1 | -0.09 | 62.50 | 0 | – | -8,565.30 | -19 | -19 |
| 2026: Q2 | -0.09 | 35.70 | 1 | – | -3,909.30 | -23 | -23 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.44 | -0.49 – -0.36 | 4 | 26.3% | 4 |
| 12/31/2027 | -0.39 | -0.47 – -0.35 | 3 | 9.9% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -73.5%
- ROCE > 15% -71.0%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Ali Faraz | Chief Executive Officer | Other | 122,000 | 0.00 | – |
| Sep 10, 2026 | Tingley Whittemore | Chief Medical Officer | Other | 49,000 | 0.00 | – |
| Aug 17, 2026 | Ali Faraz | Chief Executive Officer | Sell | 7,406 | 0.7097 | 5,256 |
| Aug 17, 2026 | Ali Faraz | Chief Executive Officer | Sell | 5,020 | 0.7097 | 3,563 |
| Aug 17, 2026 | Ali Faraz | Chief Executive Officer | Sell | 3,969 | 0.7098 | 2,817 |
| Aug 17, 2026 | Ali Faraz | Chief Executive Officer | Sell | 5,837 | 0.7097 | 4,143 |
| Aug 17, 2026 | Tingley Whittemore | Chief Medical Officer | Sell | 2,279 | 0.7098 | 1,618 |
| Aug 17, 2026 | Tingley Whittemore | Chief Medical Officer | Sell | 1,871 | 0.7098 | 1,328 |
| Aug 17, 2026 | Tingley Whittemore | Chief Medical Officer | Sell | 1,637 | 0.7098 | 1,162 |
The company
About the Company
Tenaya Therapeutics, Inc., ein biotechnologisches Unternehmen im klinischen Stadium, erforscht, entwickelt und liefert Therapien für Herzerkrankungen in den Vereinigten Staaten. Sein führender Produktkandidat umfasst TN-201, eine Gentherapie für die mit dem Myosin-bindenden Protein C3 assoziierte hypertrophe Kardiomyopathie, die sich in einer Phase-1b/2-Studie befindet; TN-401, eine Gentherapie für die mit Plakophilin 2 assoziierte arrhythmogene rechtsventrikuläre Kardiomyopathie, die sich in einer Phase-1b/2-Studie befindet; sowie TN-301, ein niedermolekularer Histondeacetylase-6-Hemmer für Herzinsuffizienz mit erhaltener Ejektionsfraktion, der sich in einer Phase-1-Studie befindet. Das Unternehmen entwickelt seine Produkte durch Genzugabe, Gen-Editierung, Gen-Stilllegung und zelluläre Regeneration. Es unterhält eine Forschungskooperation mit Alnylam Pharmaceuticals, Inc. zur Identifizierung und Validierung neuer Gen-Zielstrukturen für die potenzielle Behandlung von Herz-Kreislauf-Erkrankungen. Tenaya Therapeutics, Inc. wurde 2016 gegründet und hat ihren Hauptsitz in South San Francisco, Kalifornien.
- Employees
- 70
- Headquarters
- South San Francisco, CA
- Address
- 171 Oyster Point Boulevard, 94080 South San Francisco, United States
- Phone
- 650 825 6990
- Website
- tenayatherapeutics.com
- IPO Date
- 07/30/2021
- ISIN
- US87990A1060
Management
| Name | Title | Birth Year |
|---|---|---|
| Faraz Ali M.B.A. | President, CEO & Director | 1973 |
| Deepak Srivastava M.D. | Scientific Founder, Chairman of Scientific Advisory Board & Director | 1967 |
| Whittemore G. Tingley M.D., PH.D. | Chief Medical Officer | 1968 |
| Eric N. Olson Ph.D. | Scientific Founder & Member of Scientific Advisory Board | – |
| Bruce R. Conklin M.D. | Scientific Founder | – |
| Saptarsi Haldar M.D. | Scientific Founder | – |
| Sheng Ding Ph.D. | Scientific Founder | – |
| Benoit G. Bruneau Ph.D. | Scientific Founder | – |
| Eric Hyllengren | CFO & Principal Accounting Officer | 1975 |
| Kee-Hong Kim Ph.D. | Chief Technology Officer | 1966 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.